• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

    4/5/24 1:06:12 PM ET
    $ACB
    $AGS
    $AIH
    $ARDX
    Medicinal Chemicals and Botanical Products
    Health Care
    Miscellaneous manufacturing industries
    Consumer Discretionary
    Get the next $ACB alert in real time by email

    Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.

    Byrna Technologies posted quarterly sales of $16.65 million, topping market estimates of $11.49 million, according to data from Benzinga Pro. The company also said its CFO David North will retire later this year.

    Byrna Technologies shares jumped 7.1% to $14.74 on Friday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • MediaCo Holding Inc. (NASDAQ:MDIA) shares jumped 141.7% to $3.4106 after a 13D amended filing showed Standard General L.P. reported a 95.2% stake in the company as of April 1, 2024.
    • HUB Cyber Security Ltd. (NASDAQ:HUBC) shares climbed 67.7% to $1.7442 after the company announced $8 million in financing via a straight debt arrangement.
    • GCT Semiconductor Holding, Inc. (NASDAQ:GCTS) gained 51.8% to $8.69 after the company and Aramco signed an MOU to accelerate the development of the 4G and 5G ecosystem in Saudi Arabia.
    • DigiAsia Corp. (NASDAQ:FAAS) shares jumped 46% to $8.03 after falling 18% on Thursday.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) gained 37% to $3.18.
    • Destiny Tech100 Inc. (NYSE:DXYZ) gained 29% to $43.26.
    • Grindrod Shipping Holdings Ltd. (NASDAQ:GRIN) shares climbed 27.8% to $13.44 after the company announced a selective capital reduction.
    • 22nd Century Group, Inc. (NASDAQ:XXII) gained 26.4% to $1.87 after dipping 16% on Thursday. On March 28, 22nd Century reported fourth-quarter earnings and announced a stock split of 1-for-16.
    • MiNK Therapeutics, Inc. (NASDAQ:INKT) rose 26.2% to $1.6913.
    • Kazia Therapeutics Limited (NASDAQ:KZIA) rose 17% to $0.39.
    • Sunshine Biopharma, Inc. (NASDAQ:SBFM) rose 16.5% to $0.1075. Sunshine Biopharma recently posted FY23 operating results.
    • SuperCom Ltd. (NASDAQ:SPCB) shares gained 16.4% to $0.2455 after jumping 19% on Thursday.
    • Envoy Medical, Inc. (NASDAQ:COCH) rose 15.5% to $6.77. Envoy Medical recently reported better-than-expected financial results.
    • Outset Medical, Inc. (NASDAQ:OM) climbed 14.2% to $2.2150.
    • Kura Sushi USA, Inc. (NASDAQ:KRUS) gained 9.8% to $114.00 following the release of second-quarter results.
    • PlayAGS, Inc. (NYSE:AGS) rose 9.7% to $9.30.
    • Greenlane Holdings, Inc. (NASDAQ:GNLN) rose 9.3% to $0.57.
    • Ardelyx, Inc. (NASDAQ:ARDX) climbed 8% to $7.74. Leerink Partners analyst Roanna Ruiz initiated coverage on Ardelyx with an Outperform rating and announced a price target of $14.
    • Yatsen Holding Limited (NYSE:YSG) gained 7.8% to $2.89.
    • Spotify Technology S.A. (NYSE:SPOT) gained 4.4% to $308.95 after Pivotal Research maintained a Buy rating on the stock and raised its price target from $330 to $390.

    Losers

    • Semantix, Inc. (NASDAQ:STIX) shares fell 34.5% to $0.57 after the company announced it will voluntarily delist from the Nasdaq Global Market.
    • noco-noco Inc. (NASDAQ:NCNC) fell 19.8% to $0.2210.
    • IM Cannabis Corp. (NASDAQ:IMCC) dipped 19.6% to $0.8601.
    • Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) fell 19.2% to $0.4131 after gaining 11% on Thursday.
    • Jiuzi Holdings, Inc. (NASDAQ:JZXN) shares dipped 17.6% to $0.7250.
    • HWH International Inc. (NASDAQ:HWH) fell 17.6% to $1.8950 after jumping 46% on Thursday.
    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) declined 17.3% to $0.1188.
    • NewGenIvf Group Limited (NASDAQ:NIVF) shares fell 15.5% to $1.2673 after dipping 45% on Thursday.
    • Brooge Energy Limited (NASDAQ:BROG) fell 14.7% to $1.6198.
    • Tempest Therapeutics, Inc. (NASDAQ:TPST) dipped 14.4% to $3.85.
    • Ermenegildo Zegna N.V. (NYSE:ZGN) shares fell 14% to $11.99 as the company reported FY23 financial results.
    • DoubleDown Interactive Co., Ltd. (NASDAQ:DDI) dipped 12.5% to $8.91.
    • Reliance Global Group, Inc. (NASDAQ:RELI) fell 11.7% to $0.4678 after reporting a loss for the fourth quarter.
    • LAMF Global Ventures Corp. I (NASDAQ:LGVC) fell 11.5% to $9.55.
    • Biodesix, Inc. (NASDAQ:BDSX) fell 11.2% to $1.34 after the company announced pricing of its oversubscribed and upsized underwritten offering of common stock and concurrent private placement.
    • Altice USA, Inc. (NYSE:ATUS) fell 9.9% to $2.3169 after Wells Fargo downgraded the stock from Equal-Weight to Underweight and lowered its price target from $2 to $1.
    • Aurora Cannabis Inc. (NASDAQ:ACB) declined 6.4% to $6.61.

     

    Now Read This: Netflix To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Friday

    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB
    $AGS
    $AIH
    $ARDX

    CompanyDatePrice TargetRatingAnalyst
    Biodesix Inc.
    $BDSX
    2/27/2026Mkt Perform → Outperform
    William Blair
    Spotify Technology S.A.
    $SPOT
    2/26/2026$586.00Neutral → Buy
    Arete
    Ermenegildo Zegna N.V.
    $ZGN
    2/12/2026$11.00Equal-Weight
    Morgan Stanley
    Spotify Technology S.A.
    $SPOT
    2/11/2026$875.00 → $420.00Buy → Hold
    Pivotal Research Group
    Ermenegildo Zegna N.V.
    $ZGN
    2/5/2026$11.50Neutral → Buy
    UBS
    Spotify Technology S.A.
    $SPOT
    1/30/2026$650.00Neutral → Buy
    Citigroup
    Aurora Cannabis Inc.
    $ACB
    1/27/2026Buy
    Canaccord Genuity
    Spotify Technology S.A.
    $SPOT
    1/27/2026$487.00Neutral
    MoffettNathanson
    More analyst ratings

    $ACB
    $AGS
    $AIH
    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    10/20/23 4:37:52 AM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZAH issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:43:04 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XPHOZA™ issued to ARDELYX INC

    Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

    10/18/23 4:37:08 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AGS
    $AIH
    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ACB
    $AGS
    $AIH
    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tivani Tier-1 Critical Minerals Project Enters Pre-Construction; HUB Cyber Security Embeds Trust Infrastructure

    TEL AVIV, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- HUB Cyber Security Ltd. (NASDAQ:HUBC) ("HUB" or the "Company"), announced that the Tivani Tier-1 Critical Minerals Project being undertaken by Ferrox Critical Minerals Ltd. ("Ferrox") has formally entered its pre-construction stage and that HUB has commenced phased embedding of its Trust Infrastructure across contractor verification, governance and capital sequencing workflows as the Tivani project advances toward its targeted 2027 commencement of production. The fully permitted Tier-1 Tivani project, located in Limpopo Province, South Africa, has initiated detailed engineering, procurement alignment and construction sequencing activitie

    2/27/26 9:00:00 AM ET
    $HUBC
    Computer Communications Equipment
    Telecommunications

    Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

    Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin," said Scott Hutton, Chief Executive Officer. "We exceed

    2/26/26 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

    100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease36 patients with relapsed/refractory multiple myeloma treated to date across two studiesTempest plans to submit a U.S. IND and, subject to clearance, initiate a U.S. registrational study in 2026 BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced cell therapy and small molecule product ca

    2/25/26 7:59:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AGS
    $AIH
    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix upgraded by William Blair

    William Blair upgraded Biodesix from Mkt Perform to Outperform

    2/27/26 8:20:07 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Spotify upgraded by Arete with a new price target

    Arete upgraded Spotify from Neutral to Buy and set a new price target of $586.00

    2/26/26 7:10:22 AM ET
    $SPOT
    Broadcasting
    Consumer Discretionary

    Morgan Stanley resumed coverage on Zegna Group with a new price target

    Morgan Stanley resumed coverage of Zegna Group with a rating of Equal-Weight and set a new price target of $11.00

    2/12/26 7:24:22 AM ET
    $ZGN
    Apparel
    Consumer Discretionary

    $ACB
    $AGS
    $AIH
    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $260,621 worth of shares (41,666 units at $6.25), decreasing direct ownership by 1% to 1,836,153 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/25/26 4:13:00 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mott David M bought $1,946,331 worth of shares (333,333 units at $5.84), increasing direct ownership by 11% to 3,302,918 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 9:01:11 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Bishop John E sold $18,586 worth of shares (3,179 units at $5.85), decreasing direct ownership by 0.93% to 339,151 units (SEC Form 4)

    4 - ARDELYX, INC. (0001437402) (Issuer)

    2/23/26 8:54:33 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $AGS
    $AIH
    $ARDX
    SEC Filings

    View All

    Envoy Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

    8-K - Envoy Medical, Inc. (0001840877) (Filer)

    2/27/26 9:11:14 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Greenlane Holdings Inc.

    DEF 14A - Greenlane Holdings, Inc. (0001743745) (Filer)

    2/26/26 4:21:12 PM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    SEC Form 10-K filed by Biodesix Inc.

    10-K - BIODESIX INC (0001439725) (Filer)

    2/26/26 4:06:05 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $ACB
    $AGS
    $AIH
    $ARDX
    Leadership Updates

    Live Leadership Updates

    View All

    Greenlane Appoints Jason Hitchcock as Chief Executive Officer to Advance Digital Asset Treasury Strategy

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Greenlane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN) today announced the appointment of Jason Hitchcock as its Chief Executive Officer, effective immediately. Mr. Hitchcock is a technology executive with over 15 years of experience building and scaling revenue engines across SaaS, blockchain infrastructure, and decentralized finance. He joins Greenlane as the Company continues to execute its Berachain-focused Digital Asset Treasury ("DAT") strategy, combining disciplined capital allocation with active ecosystem participation through validator operations, staking, and liquidity provisioning. Technology Leadership and Ent

    2/18/26 8:00:00 AM ET
    $GNLN
    Durable Goods
    Consumer Discretionary

    MediaCo Appoints Maire Mason to Lead Local Radio and Television Operations, Driving Major New York Market Shift

    Veteran Executive Joins MediaCo to Oversee NYC, Chicago, and Denver with Additional Expansion Planned MediaCo Holding Inc. (NASDAQ:MDIA) today announced the appointment of Maire Mason as Vice President and General Manager of Local MediaCo Markets, marking a significant leadership move in the New York radio and television landscape. In this role, Mason will oversee MediaCo's local radio and television operations across New York City, Chicago, and Denver, with responsibility for marquee brands including HOT 97 (WQHT-FM), WBLS-FM, Luna 107.5 (WBLS-HD2), La Buena (WQHT-HD2), and EstrellaTV's WMBC-TV in the New York tri-state area. MediaCo expects Mason's responsibilities to expand to additi

    1/26/26 8:00:00 AM ET
    $MDIA
    Broadcasting
    Consumer Discretionary

    Kura Sushi USA Announces Election of Claudia Schaefer to the Company's Board of Directors

    IRVINE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Kura Sushi USA, Inc. ("Kura Sushi" or the "Company"), (NASDAQ:KRUS), a technology-enabled Japanese restaurant concept, today announced that Claudia Schaefer has been elected to serve as an independent member of the Board of Directors effective January 21, 2026. In conjunction with Ms. Schaefer's nomination, Kim Ellis did not stand for re-election as a director, also effective January 21, 2026. Hajime Uba, President, Chief Executive Officer and Chairman of Kura Sushi, stated, "We are thrilled to announce the election of Claudia to Kura Sushi USA's Board of Directors. Claudia's deep brand and marketing background makes her an excellent addit

    1/22/26 4:05:00 PM ET
    $KRUS
    Restaurants
    Consumer Discretionary

    $ACB
    $AGS
    $AIH
    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/26/24 7:34:11 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/22/24 5:00:10 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $ACB
    $AGS
    $AIH
    $ARDX
    Financials

    Live finance-specific insights

    View All

    Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

    Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin," said Scott Hutton, Chief Executive Officer. "We exceed

    2/26/26 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Yatsen to Announce Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

    GUANGZHOU, China, Feb. 23, 2026 /PRNewswire/ -- Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE:YSG), a leading China-based beauty group, today announced that it will release its unaudited financial results for the fourth quarter and full year ended December 31, 2025, on Monday, March 2, 2026, before the open of the U.S. markets. The Company's management will hold a conference call on Monday, March 2, 2026 at 7:30 A.M. U.S. Eastern Standard Time (8:30 P.M. Beijing/Hong Kong Time) to discuss the financial results. Listeners may access the call by dialing the following numbers:United States (toll free):+1-888-346-8982International:+1-412-902-4272Mainland China (toll free):400-120-1203

    2/23/26 5:00:00 AM ET
    $YSG
    Package Goods/Cosmetics
    Consumer Discretionary

    22nd Century Group Preliminarily Reports Fourth Quarter and Full Year 2025 Financial Results

    Balance sheet strength, ended 2025 with $7.1 million in cash and debt free, supports transition to growth Continued VLN® commercial expansion drives shift toward higher margin proprietary branded products MOCKSVILLE, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced select, preliminary and unaudited financial results and operating metrics for the fourth quarter and full year ended December 31, 2025. The company anticipates releasing fourth quarter and full year 2025 earnings on or before March

    2/20/26 4:15:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care